anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Twelve weeks of 1100 mg of apple polyphenol supplementation. At the start, middle and end of the study, several measurements will take place.
PURPOSE:To obtain a central acting muscle relaxant containing tizanidine hydrochloride and a non-yellowing excipient and having suppressed yellowing tendency of tizanidine hydrochloride. CONSTITUTION:This non-yellowing agent contains tizanidine hydrochloride and excipients such as a non-yellowing binder (e.g. polysaccharide such as pullulan), a disintegrant, lactose, corn starch, crystalline cellulose and mannitol. The weight ratio of tizanidine to the excipient is 0.01-10%, preferably 0.2-1%. The agent is used in the form of tablet, capsule, dry syrup, granule, powder, injection, etc., and administered at a daily dose of 3-9mg. Tizanidine hydrochloride is useful as a skeletal muscle relaxant, especially a central acting muscle relaxant having alpha-rigidity and gamma-rigidity suppressing action, multisynaptic reflex suppressing action, anti-impingement action, etc., and effective for the treatment of muscle contraction pain and cerebral and spinal spasmic diseases.
The present invention discloses a streptokinase gene, recombination protein and preparing methods thereof, particularly a thromboclasis substance, especially a streptokinase gene, protein generated by the expression of the streptokinase gene and preparing methods thereof. The present invention also relates to a source bacterial strain of the streptokinase gene and two recombination bacterial strains containing the gene. The comparison and the function study of a nucleotide sequence and an amino acid sequence indicate that the streptokinase is a new fibrinolysin, and the activity of the streptokinase is measured to 41000 IU/mg with a fibrin plate method. The streptokinase has the functions of the oxidative damage of an antagonistic organism, and has obvious effect of inhibiting protein oxidation caused by hemoglobin, NaNO2 and H2O2. Compared with the existing thrombolysis medicine which comes into the market or is studied at home and abroad, the streptokinase (Subtilisin QK) provided by the present invention has the advantages of high activity, antioxidation, anti-PAI-1 inhibiting effect, fibrin specificity, long half-life in the blood, low repeated infarct probability and low cost. Thus, the streptokinase has important application value in the aspect of treating cardiovascular diseases.
The subject will be intubated according to the design of group 1. The remifentanil target will be 3 ng/ml remifentanil. The propofol concentration will aim a BIS of 30.
Human and animal studies suggest cyclooxygenase-inhibitors (COX-inhibitors) decrease the production of inflammatory mediators. Studies also suggest that COX inhibitors attenuate increases in corticosterone and eicosanoid levels after endotoxin injection. COX inhibitors also appear to have anticancer effects, inhibiting angiogenesis, tumor growth, and metastatic burden. These results suggest a role for IV ibuprofen in preventing untoward inflammatory responses, shortening post-surgical convalescence, improving patient satisfaction, and reducing the rate of complications occurring during the recovery from surgery. However, there are no studies that have evaluated the relationship between administration of IV ibuprofen, ensuing immunomodulation, and long-term outcomes.

Study Objective. The aim of the proposed study is to examine the effect of intravenous(IV) ibuprofen on the inflammatory response in major surgery. More importantly, the investigators will correlate changes in the concentration of inflammatory mediators with meaningful clinical outcomes.
BACKGROUND: As the number of total shoulder arthroplasty (TSA) procedures increases, there is a growing interest in improving patient outcomes, limiting costs, and optimizing efficiency. One approach has been to transition these surgeries to an outpatient setting. Therefore, the purpose of this study was to conduct an age-stratified analysis comparing the 90-day postoperative outcomes of primary TSA in the same-day discharge (SDD) and inpatient (IP) settings with a specific focus on the super-elderly.
METHODS: This retrospective study included all patients who underwent primary anatomic or reverse TSA between January 2018 and December 2021 in ambulatory and IP settings. The outcome measures included length of stay (LOS), complications, hospital charges, emergency department (ED utilization), readmissions, and reoperations within 90 days following TSA. Patients with LOS ≤8 hours were considered as SDD, and those with LOS >8 hours were considered as IP. P < .05 was considered statistically significant.
RESULTS: There were 121 and 174 procedures performed in SDD and IP settings, respectively. There were no differences in comorbidity indices between the SDD and IP groups (American Society of Anesthesiologists score P = .12, Elixhauser Comorbidity Index P = .067). The SDD cohort was younger than the IP group (SDD 67.0 years vs. 73.0 IP years, P < .001), and the SDD group higher rate of intraoperative tranexamic acid use (P = .015) and lower estimated blood loss (P = .009). There were no differences in 90-day overall minor (P = .20) and major complications (P = 1.00), ED utilization (P = .63), readmission (P = .25), or reoperation (P = .51) between the SDD and IP groups. When stratified by age, there were no differences in overall major (P = .80) and minor (P = .36) complications among the groups. However, the LOS was directly correlated with increasing age (LOS = 8.4 hours in ≥65 to <75-year cohort vs. LOS = 25.9 hours in ≥80-year cohort; P < .001). There were no differences in hospital charges between SDD and IP primary TSA in all 3 age groups (P = .82).
CONCLUSION: SDD TSA has a shorter LOS without increasing postoperative major and minor complications, ED encounters, readmissions, or reoperations. Older age was not associated with an increase in the complication profile or hospital charges even in the SDD setting, although it was associated with increased LOS in the IP group. These results suggest that TSA can be safely performed expeditiously in an outpatient setting.
NEW MATERIAL:A phosphatidylcholine-type polymerizable phospholipid of formula I (n is 6-12; l is 13-21). USE:A microcapsule material, photoresist material and surface-modification agent for various materials. Since the compound is resistant to decomposition with phospholipase A2, a microcapsule having excellent stability in living body can be produced from the compound. PREPARATION:For example, the compound of formula II is activated e.g. by reacting with oxalyl chloride and condensed with a glycerol derivative of formula III usually in a solvent such as anhydrous THF in the presence of a reaction acceleration assistant (e.g. N,N-dimethylaminopyridine) at 0-30 deg.C. The obtained compound of formula IV is made to react with the compound of formula V in a solvent such as anhydrous benzene in the presence of triethylamine, etc.
PURPOSE:To obtain an easily absorbable solid preparation of a hardly soluble drug having remarkably improved dispersibility, by mixing a hardly soluble drug with a phospholipid and a disintegrant. CONSTITUTION:A hardly soluble drug is dissolved or dispersed together with a phospholipid in an organic solvent (e.g. methanol), a disintegrant is added to the solution or dispersion and the organic solvent is removed from the mixture to obtain the objective preparation. As an alternative method, the objective preparation is produced by mixing and crushing a hardly soluble drug together with a phospholipid and a disintegrant in the absence of solvent. The hardly soluble drug is those having a water-solubility of <=5mg/ml at 20 deg.C, e.g. nifedipin, prazosin, etc. The phospholipid is e.g. lecithin, hydrogenated lecithin, etc., and the disintegrant is e.g. croscarmellose sodium, crosslinked polyvinyl pyrrolidone, etc. The amounts of the phospholipid and disintegrant are 0.5-30 pts.wt. and 1-80pts.wt. per 1pt.wt. of the hardly soluble drug and the weight ratio of phospholipid to disintegrant is 1:0.5-30.
LY3023414 administered orally BID for two 28 day cycles to participants with advanced/metastatic breast cancer; participants receiving benefit may continue until disease progression or discontinuation. 500 mg fulvestrant administered IM once every 28 days.
Patients receive GNC-035 as a 24-hour continuous intravenous infusion (cIV, QD) for 2 weeks (a 2-week cycle). Participants with no intolerable AEs could continue for another three cycles.
A system is described for long-term controlled release delivery of a drug or a therapeutic agent. According to the invention, one or more drugs or therapeutic agents contained in microspheres are mixed with a temperature sensitive hydrogel which is then introduced directly to the desired situs of the drug or therapeutic agent. The temperature sensitive hydrogel may also contain a drug or a therapeutic agent, for example, a pain relieving drug, for a short-term controlled release. The temperature sensitive hydrogel is in liquid state at room temperature, but upon injection, shortly becomes gelatinous. This system is particularly suitable for treatment of diseases, disorders, or conditions, for example, tumors, discogenic back pain, or arthritis, warranting localized administration of a drug or a therapeutic agent. In addition, the specification provides a method for production of a drug- or therapeutic agent-containing microspheres.
Apparatus, e.g. a syringe, for dispensing foam includes means for ensuring that only foam of adequate quality is dispensed. In use, the syringe may be filled from a pressurised canister which generates foam e.g. for therapeutic use in treating varicose veins. An initial quantity of foam dispensed from the canister may be of inadequate quality in which case it should not be used: the syringe includes means to ensure that this initial quantity of foam is diverted to a waste port or to an internal waste chamber e.g. located in the syringe plunger. Foam dispensed after the initial quantity of poor quality foam is stored in the main barrel of the syringe ready for administration to a patient in need of treatment.
100% oxygen given to patient before induction of anesthesia (asleep) is the standard clinical care. However, studies using various methods have shown differences in terms of the optimal time, technique and number of breaths needed for efficient oxygenation. The only difference to the standard pre-anesthesia care is that we will record the time to raise patient oxygen to 90%. Age is recorded to ensure that the subjects fall within our inclusion criteria. The weight (W) in kilograms and height (H) in meters will be used to calculate the body mass index (BMI): BMI = W/H2. Alveolar oxygen uptake is dependent on respiratory rate, heart rate, blood pressure, temperature and hemoglobin level. These parameters are measured in order to identify factors that may affect the accuracy of the study. We will record the pulse oximetry value to note the initial oxygen saturation on room air and after the oxygenation.

Facial hair and mask fit are recorded to assess possible failure of an optimal facemask seal. End-tidal carbon dioxide (FE'CO2) is also measured to ensure an adequate facemask seal. Anxiety can increase the respiratory rate, heart rate and affect patient compliance with a fitted facemask. All of the aforementioned values are recorded to assess reasons for possible failure of the preoxygenation technique and inaccurate results.
Receive ACTH at the dose of 40 units sub-cutaneously for up to 12 weeks. If at day 91 no response has been shown, you will have the option to increase the dose of ACTH to 80 units for up to an additional 120 days.
BACKGROUND: To study the risk factors associated with misplacement of freehand pedicle screws through a posterior approach for degenerative scoliosis.
METHODS: A total of 204 patients who underwent posterior pedicle screw-rod system surgery for degenerative scoliosis in our hospital from December 2020 to December 2023 were retrospectively analyzed. Patient demographics, radiographic accuracy, and surgery-related information were recorded.
RESULTS: A total of 204 patients were included. A total of 2496 screws were placed. 2373 (95.07%) were in good position. Misplacement screws were 123 (4.93%). None of the patients had postoperative spinal nerve symptoms due to screw malposition. The misplacement rate of thoracic (T10-T12) pedicle screws was 11.11% (60/540). Misplacement of pedicle screws in the lumbar spine (L1-L5) was 3.22% (63/1956). Age, gender, surgeon, and operation time had no significant effect on misplacement of pedicle screws (P>0.05). Body mass index, Hu value, number of screw segments, Cobb angle, vertebral rotation, and spinal canal morphology had some correlation with pedicle screw misplacement. Among them, BMI, Hu value, number of screw segments, Cobb angle, and vertebral rotation grade were independent risk factors for PS misplacement (P<0.05). The height of the posterior superior iliac spine had a significant effect on pedicle screw misplacement in the lower lumbar spine (L4/5) (P<0.05).
CONCLUSION: BMI, Hu value, number of screw levels, Cobb angle, and vertebral rotation grade were independent risk factors for pedicle screw misplacement in patients with degenerative scoliosis. Posterior superior iliac spine height has a large impact on PS placement in the lower lumbar spine. Patients with degenerative scoliosis should be preoperatively planned for the size and direction of the placed screws by X-ray and CT three-dimensional, to reduce the misplacement rate of pedicle screws.
PURPOSE: The purpose of this study was to assess fine motor skills and reading proficiency in adults with amblyopia and/or strabismus, and to determine how these relate to clinical measures of vision and self-reported vision-related quality of life.
METHODS: Fine motor skills (Manual dexterity - Bruininks-Oseretsky Test of Motor Proficiency [BOT-2]) and reading performance (International Reading Speed Texts [IReST]) were assessed in 23 adults with non-strabismic amblyopia, 20 with non-amblyopic strabismus, 52 with both amblyopia and strabismus, and 19 with normal visual development. Visual acuity and binocular function score (BFS), obtained from stereoacuity and presence/absence of suppression, were also determined. Vision-related quality of life was assessed with the Amblyopia and Strabismus Questionnaire (A&SQ) in those with amblyopia and/or strabismus. Statistical analysis included ANOVA and multiple regression models.
RESULTS: Participants with amblyopia and/or strabismus exhibited poorer performance in all five manual dexterity sub-items and the overall standardized score (P < 0.05). The reading rate was significantly slower across all amblyopia/strabismus groups (P < 0.05). Poorer fine motor skills and slower reading performance were associated with each other (R = 0.29). Clinical visual characteristics (visual acuity [VA], BFS, and presence of strabismus) explained 39% of the variance in fine motor skills score (R2 = 0.39), however, these explained only 6% of the variance in reading speed (R2 = 0.06). Self-report of functional ability related most to BFS, whereas psychosocial impact related to the presence of strabismus. The clinical and functional characteristics predicted 4% of the variance in functional impact score (R2 = 0.038) and explained 16% of the variance in psychosocial impact score (R2 = 0.16).
CONCLUSIONS: The functional and psychosocial effects of amblyopia and strabismus are common and persist into adulthood, with outcomes inadequately accounted for by clinical measures of vision.
A method of treating inflammation, by administering an effective amount of a ß2 integrin agonist to a patient, and reducing inflammation. A method of treating cancer, by administering an effective amount of a ß2 integrin agonist to a patient, and reducing tumor growth. A method of treating a patient exposed to radiation, by administering an effective amount of a ß2 integrin agonist to the patient after radiation exposure, and mitigating the effects of radiation exposure in the patient. A method of preventing effects of radiation, by administering an effective amount of a ß2 integrin agonist to the patient prior to radiation exposure, and preventing the effects of radiation exposure on the patient. A method of treating acquired bone marrow failure (BMF), by administering an effective amount of a ß2 integrin agonist to a patient. Methods of improving the health of damaged vasculature in a patient and activating ß2 integrins.
For the production of a corticotropic substance, the serum of gravid mares is treated, e.g. at pH5, with an organic water-miscible liquid, e.g. an alcohol or ketone, so as to precipitate the serum albumins and globulins, the separated mother liquor is treated with a second addition of a water-miscible organic liquid to precipitate the corticotropic substance, which is formed of at least three components, in admixture with the gonadotropic hormones, and the precipitate is thoroughly washed with 50 per cent aqueous alcohol to free it from the gonadotropic hormones and other impurities.  The same organic liquid may be used in both precipitations, and is higher in relation to the mother liquid or serum in the second than in the first.  The crude precipitate freed from the gonadotropic hormones is treated with water or alkaline solution at pH10, and precipitated by an organic liquid, e.g. alcohol, this operation being repeated as desired. The three components may be separated, substance C by dialysis, and factors A and B by fractional precipitations. Specification 503,642 is referred to.
Patients will receive a single antispasmodic muscarinic suppository after induction of anesthesia but before insertion of urological scope for surgery. The suppository is composed of Belladonna (16.2 mg) and Opium (30 mg) in a water soluble base manufactured as Belladonna and Opium Supprettes.
The invention discloses a new use of miR-329. The new use comprises an application of the miR-329 or a miR-329 modifier in preparation of drugs for prevention and/or treatment of ischemic ocular diseases. Experiments prove that miR-329 gene treatment significantly alleviates the severity extent of the ischemic ocular diseases. An action mechanism mainly comprises that the miR-329 can inhibit activation of VEGF-induced downstream signaling pathways in endothelial cell and expression of multiple pro-angiogenic genes, then angiogenesis and migration abilities of the endothelial cell are inhibited, and thus the abnormal angiogenesis and migration of the ischemic ocular diseases are improved, and retinal vascular tortuosity expansion, hemorrhage and leakage, vascular cluster abnormal growth and other symptoms are relieved. With normalization of a retinal structure and morphology, fundus hemorrhage, blurred vision, visual field loss and other clinical symptoms can be relieved, and occurrence and development of diseases are inhibited. Therefore, the miR-329 can prevent and/or treat the ischemic ocular diseases and has a broad application prospect.
PURPOSE:To provide an anti-inflammatory agent for external use, containing an oil having a specific melting point as an active component, having high safety, and exhibiting remarkable anti-inflammatory effect. CONSTITUTION:The objective composition can be prepared by using an oil having a melting point of <=37 deg.C, preferably olive oil, magnolia oil, sunflower oil, oenothera oil, squalane, alpha-olefin oligomer, 2-ethylhexanoic acid, isostearic acid, 2-ethylhexanoic acid triglyceride, etc. as an active component. The anti- inflammatory action of the above oil can be further improved by the addition of a silicone oil. The silicone oil is preferably the one having a viscosity of <=10cs and 25 deg.C, e.g. methylpolysiloxane, methylphenylpolysiloxane, etc. Especially, the agent of the present invention is used as an oily anti-inflammatory agent for external use. It has extremely high safety.
A topical compsn., in the form of an emulsion, comprises a cpd. of the FK506 class, a physiologically acceptable alkanediol, ether diol or diether alcohol contg. up to 8 C atoms as solvent for the cpd. of the FK506 class, an unsatd. fatty alcohol and water. Also claimed are a topical compsn. comprising a macrolide in suspension and the use of an unsatd. fatty alcohol to stabilise a macrolide in a pharmaceutical compsn..
PURPOSE:To obtain titled glass which is highly resistant to water and maintains the strength with extremely little deterioration with age by subjecting the crystallized glass obtd. by a heat treatment of calcium phosphate glass to a treatment to make the glass porous then bringing the glass into contact with a soln. contg. >=1 kinds of ions among Ca, Ba and B and further subjecting the glass to a heat treatment. CONSTITUTION:The glass raw material consisting of the glass compsn. contg., for example, 45-50mol% CaO, 50-55mol% P2O5 or said compsn. added with <=10% Al2O3 and SiO2 is heated to 1,200-1,400 deg.C and is vitrified. The fused glass is molded to a prescribed shape by a pulling up method, etc. the glass molding is subjected to a heating treatment at, for example, 500-850 deg.C and is crystallized. The crystallized glass is immersed in, for example, water and is heated and pressurized at 100-200 deg.C under 1-15atm by which the glass is made porous. The glass molding which is made porous is brought into the liquid contg. ions of Ca, Ba and B to impregnate the ions therein. The crystallized glass after the impregnation treatment is held at 300-900 deg.C by which the intended calcium phosphate crystallized glass is obtd.
AIMS: Guidelines recommend non-invasive positive pressure ventilation (NPPV) for patients with acute decompensated heart failure (ADHF) with an inadequate response to initial oxygen therapy. During Japan's coronavirus disease 2019 pandemic, NPPV use in emergency departments (EDs) was limited due to aerosol-spreading concerns. This study compared the respiratory management and clinical outcomes of patients with ADHF in EDs before and during the pandemic.
METHODS AND RESULTS: This retrospective cohort study was conducted at a single centre in Japan using hospital data from September to November 2019 (before the pandemic) and September to November 2020 (during the pandemic). Patients diagnosed with ADHF were included. Patients not responding to standard oxygen therapy were intubated or started on NPPV therapy. The primary outcome measure was discharge after death. The secondary outcomes were length of hospital stay and medical expenses. The study included 37 patients before the pandemic and 36 during the pandemic. No significant differences were found in vital signs or laboratory data between the groups. NPPV utilization decreased significantly from 26 (70.3%) to 7 (19.4%) (P < 0.01). Two patients required intubation during both periods, with no significant differences (P = 0.98). No significant intergroup disparities were observed in discharge after death (1/36 [2.7%] vs. 1/37 [2.7%]; P = 0.19), length of hospital stay (17.5 vs. 19.0 days; P = 0.65), and medical expenses (57 590 vs. 57 600 yen; P = 0.65).
CONCLUSIONS: Despite a large decrease in NPPV use before and during the pandemic, there were no significant differences in discharge after death, hospital stay, or medical expenses.